BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced and Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
We presented data that suggest bezisterim’s potential to target epigenetic-driven age deceleration as a treatment for #Alzheimers disease and other #neurodegenerative diseases of aging.
Learn more: investors.bioviepharma.com/news/news-de...
#Aging #Longevitiy #Neuroscience #Neurosky #BIVI